Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.
Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S. Stoetzer OJ, et al. Among authors: braun m. Cancer Lett. 2013 Aug 9;336(1):140-8. doi: 10.1016/j.canlet.2013.04.013. Epub 2013 Apr 21. Cancer Lett. 2013. PMID: 23612068
Survival of de novo stage IV breast cancer patients over three decades.
Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Harbeck N, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Engel J. Hölzel D, et al. Among authors: braun m. J Cancer Res Clin Oncol. 2017 Mar;143(3):509-519. doi: 10.1007/s00432-016-2306-1. Epub 2016 Nov 16. J Cancer Res Clin Oncol. 2017. PMID: 27853869
Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience.
Stoetzer O, Di Gioia D, Issels RD, Abdel-Rahman S, Mansmann U, Lindner LH, Gluz O, Würstlein R, Braun M, Hamann M, Edler von Koch F, Harbeck N, Salat C. Stoetzer O, et al. Among authors: braun m. Breast Care (Basel). 2021 Apr;16(2):173-180. doi: 10.1159/000507473. Epub 2020 May 12. Breast Care (Basel). 2021. PMID: 34012372 Free PMC article.
Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.
Braun M, Kriegmair A, Szeterlak N, Andrulat A, Schrodi S, Kriner M, Hanusch C, Hamann M, Stoetzer O, Pölcher M. Braun M, et al. Breast Care (Basel). 2022 Jun;17(3):288-295. doi: 10.1159/000521096. Epub 2021 Nov 26. Breast Care (Basel). 2022. PMID: 35957951 Free PMC article.
Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kübler K, Büttner R, Kuhn WC, Hernando JJ. Pölcher M, et al. Among authors: braun m. Cancer Immunol Immunother. 2010 Jun;59(6):909-19. doi: 10.1007/s00262-010-0817-1. Epub 2010 Jan 20. Cancer Immunol Immunother. 2010. PMID: 20087581 Free PMC article. Clinical Trial.
2,420 results